These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31144994)

  • 1. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
    Wang Y; Yu RZ; Henry S; Geary RS
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
    Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of GalNAc
    Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
    Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
    Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
    Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
    Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
    Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
    Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
    Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
    Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
    Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of modular conjugation strategy for
    Yamamoto T; Sawamura M; Terada C; Kashiwada K; Wada F; Yamayoshi A; Obika S; Harada-Shiba M
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):109-118. PubMed ID: 31617782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Assessment of Phase 2 Data on GalNAc
    Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
    Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
    Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
    Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides.
    Nanavati C; McMullen G; Yu R; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2021 Aug; 31(4):298-308. PubMed ID: 33891483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Drug Interaction Potential of Unconjugated and GalNAc
    Shemesh CS; Yu RZ; Warren MS; Liu M; Jahic M; Nichols B; Post N; Lin S; Norris DA; Hurh E; Huang J; Watanabe T; Henry SP; Wang Y
    Mol Ther Nucleic Acids; 2017 Dec; 9():34-47. PubMed ID: 29246313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry.
    Husser C; Brink A; Zell M; Müller MB; Koller E; Schadt S
    Anal Chem; 2017 Jun; 89(12):6821-6826. PubMed ID: 28520401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
    Yu RZ; Graham MJ; Post N; Riney S; Zanardi T; Hall S; Burkey J; Shemesh CS; Prakash TP; Seth PP; Swayze EE; Geary RS; Wang Y; Henry S
    Mol Ther Nucleic Acids; 2016 May; 5(5):e317. PubMed ID: 27138177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.